Últimas noticias sobre Illumina (NASDAQ:ILMN) Bolsa

ILLUMINA INC

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Ark Invest's Cathie Wood Says Belief In Bitcoin's $1.5 Million Price Target By 2030 Has Grown

Equities

News

Markets

ETFs

ARKG

ARKK

GTLB

ILMN

IRDM

PATH

Ark Invest realizó movimientos estratégicos en el sector tecnológico, ajustando su portafolio con compras clave y ventas millonarias.

Cathie Wood apuesta por Tempus AI y AMD mientras reduce su posición en Meta

SPDR Dow Jones Industrial Average ETF Trust

GILD

NVDA

PYPL

STLA

TSLA

Las acciones del S&amp;P 500 y Nasdaq caen mientras Nvidia y Tesla sufren pérdidas. Descubre qué está impulsando la volatilidad del mercado.

Acciones en rojo: Nvidia, Tesla y PayPal sufren fuertes caídas en medio de incertidumbre

PLTR

ROKU

TWST

Ark Invest vendió más de 135.000 acciones de Palantir Technologies Inc. tras su récord en bolsa. ¿Estrategia o señal de alerta?

Cathie Wood reduce posición en Palantir (PLTR) tras resultados récord: ¿Oportunidad o advertencia?

Illumina Inc

Illumina Inc COM-WHEN ISSUED

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) raises FY2025 Adj EPS guidance from $4.20-$4.30 to $4.45-$4.55 vs $4.23 analyst estimate..

Guidance

Illumina Raises FY2025 Adj EPS Guidance from $4.20-$4.30 to $4.45-$4.55 vs $4.23 Est

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.01 by 17.24 percent. This is a 230.56 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $1.059 billion which beat the analyst consensus estimate of $1.049 billion by 0.92 percent. This is a 4.77 percent decrease over sales of $1.112 billion the same period last year.

Earnings

Earnings Beats

Illumina Q2 Adj. EPS $1.19 Beats $1.01 Estimate, Sales $1.059B Beat $1.049B Estimate

AAMI

AAPL

ABBV

ACCO

AGCO

AGIO

ALGM

ALNY

AMZN

APLS

APPF

APTV

ARGX

ASUR

ATEC

ATHM

AUPH

AXTI

BBVA

BCPC

BFAM

BIGC

BIIB

BJRI

BLDR

BOOT

BSAC

CABO

CACC

CCCS

CCEC

CDRO

CIGI

CLAR

CMCSA

CMPS

CMRE

COHN

COHU

COIN

COLM

CORT

CRAI

CUBE

CVCO

CWST

DFIN

DINO

DOUG

DSGR

Earnings Scheduled For July 31, 2025

Illumina TruSight&#x2122; Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input
Illumina's growing research and clinical oncology portfolio broadens access to critical biomarker testing
SAN DIEGO, July 30, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive genomic profiling (CGP) is a critical tool to accelerate access to precision medicine by providing a molecular tumor profile to labs advancing research in therapy selection and clinical trial eligibility. TruSight Oncology 500 version 2 (TSO 500 v2)&nbsp;offers a streamlined sample-to-analysis workflow and reflects Illumina's commitment to serving customers with the highest quality and most rigorously tested solutions.

Biotech

General

Illumina Launches TruSight Oncology 500 v2 With Built-In HRD Detection, Faster Results, And Lower Sample Requirements For Advanced Cancer Research

In the preceding three months, 12 analysts have released ratings for Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $108.17, a high estimate of $185.00, and a low estimate of $80.00. A 1.98% drop is evident in the current average compared to the previous average price target of $110.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1753711401_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Illumina is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$99.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$114.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Illumina's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Illumina's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Unveiling the Story Behind Illumina</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Breaking Down Illumina's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Illumina's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -3.25% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Illumina's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Illumina's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Illumina's ROA excels beyond industry benchmarks, reaching 2.1%. This signifies efficient management of assets and strong financial health.
Debt Management: Illumina's debt-to-equity ratio stands notably higher than the industry average, reaching 1.1. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

12 Analysts Assess Illumina: What You Need To Know

Baird analyst Catherine Ramsey maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Neutral and raises the price target from $84 to $105.

Price Target

Baird Maintains Neutral on Illumina, Raises Price Target to $105

Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.
<h3 class="wp-block-heading">Illumina&#8217;s Journey So Far</h3>
For most of its journey, Illumina followed the Adhishthana Principles closely, both on the weekly and monthly charts. One such strong alignment case took place during Phases 9 to 11, when the stock formed the Adhishthana Himalayan Formation on the weekly chart.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="854" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17104952/ILMN-Stock-Weekly-Adhishthana.png" alt="Fig.1 Illumina Stock Himlayan Formation (Source: Adhishthana.com Reports)" class="wp-image-15969" style="width:559px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17104952/ILMN-Stock-Weekly-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17104952/ILMN-Stock-Weekly-Adhishthana-300x214.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17104952/ILMN-Stock-Weekly-Adhishthana-1024x729.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17104952/ILMN-Stock-Weekly-Adhishthana-768x547.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 Illumina Stock Himlayan Formation (Source: Adhishthana.com Reports)</figcaption></figure>
In Phase 9, the stock broke out of its Cakra, which usually signals the beginning of a strong upward move. ILMN rallied by around 73% from its Phase 9 lows, marking the start of the Himalayan ascent. This rally continued into Phase 10, where the stock made its peak, just as expected under the framework.
What followed in Phase 11 was the descent, often referred to in the principles as the Wrath of Ganga. This phase is typically marked by a sharp decline, and ILMN dropped by nearly 67%, retracing all the way back to its Phase 9 breakout levels. This marked the completion of the Himalayan Formation.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="527" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110109/ILMN-Stock-Weekly-Guna-Triads--1024x527.png" alt="Fig.2 Illumina Stock Guna Triads (Source: Adhishthana.com Reports)" class="wp-image-15973" style="width:495px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110109/ILMN-Stock-Weekly-Guna-Triads--1024x527.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110109/ILMN-Stock-Weekly-Guna-Triads--300x155.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110109/ILMN-Stock-Weekly-Guna-Triads--768x396.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110109/ILMN-Stock-Weekly-Guna-Triads-.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Fig.2 Illumina Stock Guna Triads (Source: Adhishthana.com Reports)</figcaption></figure>
Post Phase 11, the stock failed to show any meaningful signs of recovery and continued to trade with a weak and bearish outlook. It then entered what is known in the Adhishthana framework as the Guna Triads, Phases 14, 15, and 16. These three phases are critical, as they determine whether the stock has the potential to reach Nirvana, the highest point in its cycle, during Phase 18.
In Illumina's case, none of the Guna phases showed Satoguna, which is a clean and decisive bullish move. This lack of strength signals that the stock is unlikely to attain Nirvana in its Phase 18, which runs from 24 November 2025 to 16 May 2027.
While this already points to underperformance on the weekly chart for the next couple of years, a look at the monthly chart reveals even deeper concerns.
<h3 class="wp-block-heading">Monthly Chart: The Real Concern</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="604" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110935/ILMN-Monthly-Chart-.png" alt="Fig.3 Illumina Monthly Chart (Source: Adhishthana.com Reports)" class="wp-image-15974" style="width:622px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110935/ILMN-Monthly-Chart-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110935/ILMN-Monthly-Chart--300x151.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110935/ILMN-Monthly-Chart--1024x515.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17110935/ILMN-Monthly-Chart--768x387.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.3 Illumina Monthly Chart (Source: Adhishthana.com Reports)</figcaption></figure>
Under the Adhishthana framework, stocks typically form a Cakra structure between Phases 4–8. A breakout from this structure in Phase 9 usually triggers a strong rally. But for Illumina, the opposite occurred.
The stock began building a promising Cakra early in the cycle — until Phase 6, when it broke the Cakra on the flip side, initiating what's known as the Move of Pralayā.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"When the underlying breaks the Cākra on the flip side, it typically draws consolidation up to the Guna triads. The movement after the break is typically highly significant, and the selling momentum is extremely strong. Such a move shall be called the Move of Pralayā." — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
The result? A collapse of over 83%, and a long road ahead. According to the principles, a stock in the Move of Pralayā must be avoided until the end of Phase 13, which for ILMN concludes 18 years from now!!
<h3 class="wp-block-heading">Investor Outlook</h3>
The Move of Pralayā isn&#8217;t triggered by ordinary market forces — it reflects deep, structural weakness in the stock fundamentally. While there may be interim rallies, these are unlikely to be sustainable or signal lasting recovery.
<ul class="wp-block-list">
<li>Short-term: With Nirvana ruled out in Phase 18 on the weekly chart, any gains are likely to be fleeting. </li>
<li>Long-term: The stock is trapped in the aftermath of Pralayā, with more downside and sideways action expected for years. </li>
</ul>
Conclusion: ILMN should be avoided by long-term investors. Traders may explore advanced, range-bound strategies — but these are suitable only for professionals due to liquidity and skewed option chains.
Curious About the Move of Pralayā?
Read more on how structural breakdowns can shape long-term stock behavior:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46398344/why-centenes-40-drop-doesnt-necessarily-signal-a-buy" target="_blank" rel="noreferrer noopener">Why Centene&#8217;s 40% Drop Doesn't Signal a Buy </a></li>
<li><a href="https://www.benzinga.com/markets/equities/25/07/46372872/mongodb-stock-weak-structure-suggests-prolonged-slump" target="_blank" rel="noreferrer noopener">MongoDB&#8217;s Structure Suggests Trouble Ahead </a></li>
</ul>
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Technicals

Opinion

Signals

Trading Ideas

Illumina Stock: What Went Wrong And Why It's Best To Stay Away

Scotiabank analyst Sung Ji Nam downgrades Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Sector Outperform to Sector Perform and announces $125 price target.

Downgrades

Scotiabank Downgrades Illumina to Sector Perform, Announces $125 Price Target

ILMN: -4% &#x7C; <a href="https://www.benzinga.com/node/46315411">Illumina shares are trading lower after Citigroup downgraded the stock from Neutral to Sell and lowered its price target from $85 to $80.</a>
&nbsp;
SOBR: 106% &#x7C; <a href="https://www.benzinga.com/node/46308288">SOBR Safe shares are trading higher after the company announced it has been granted European patent number EP4171362.</a>
&nbsp;
AES: 19% &#x7C; <a href="https://www.benzinga.com/node/46308959">'Power Firm AES Explores Options Amid Takeover Interest'- Bloomberg</a>

Movers

SOBR

Market-Moving News for July 9th

WIIM

Illumina shares are trading lower after Citigroup downgraded the stock from Neutral to Sell and lowered its price target from $85 to $80.

Citigroup analyst Patrick Donnelly downgrades Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Neutral to Sell and lowers the price target from $85 to $80.

Citigroup Downgrades Illumina to Sell, Lowers Price Target to $80

In the last three months, 11 analysts have published ratings on Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a downward trend, the current average is 8.18% lower than the prior average price target of $114.55. 
<img src="https://www.benzinga.com/files/images/story/2025/1752001284_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Illumina. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$99.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$114.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$92.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$77.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Illumina's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Illumina's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Unveiling the Story Behind Illumina</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Illumina's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Illumina's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.25%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Illumina's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Illumina's ROE stands out, surpassing industry averages. With an impressive ROE of 5.53%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Illumina's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.1%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.1, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Illumina Stands With Analysts

Evercore ISI Group analyst Vijay Kumar maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and raises the price target from $116 to $128.

Evercore ISI Group Maintains Outperform on Illumina, Raises Price Target to $128

<a href="https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter">https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter</a>

BRKR

QTRX

'NIH halts grant terminations 'effective immediately,' email says'- Stat News

Barclays analyst Luke Sergott maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Underweight and raises the price target from $77 to $85.

Barclays Maintains Underweight on Illumina, Raises Price Target to $85

On Monday, Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) agreed to acquire Standard BioTools&#8217; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) subsidiary, SomaLogic.
Following the announcement of the acquisition, Standard BioTools&#8217; stock experienced a significant surge.
The deal consideration includes $350 million in cash payable at closing plus up to $75 million in near-term performance-based milestones and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46048517/illumina-to-acquire-somalogic-accelerating-its-proteomics-business-and-advancing-the-companys-mult" rel="noreferrer noopener">performance-based royalties</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46056104/why-is-compass-pathways-stock-trading-lower-on-monday" rel="noreferrer noopener">Why Is Compass Pathways Stock Trading Lower On Monday?</a>
&#8220;The acquisition of SomaLogic will enhance Illumina&#8217;s presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future,&#8221; said Jacob Thaysen, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">CEO of Illumina</a>.
&#8220;Illumina and SomaLogic have partnered closely for more than three years, and this combination&nbsp;increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling,&#8221; Thaysen added.
The transaction builds on a co-development agreement Illumina established with SomaLogic in December 2021 to bring the SomaScan Proteomics Assay onto Illumina&#8217;s high-throughput next-generation sequencing (NGS) platforms.
Illumina Protein Prep is currently in use with nearly 40 early-access customers globally and will become available to all customers starting in the third quarter of 2025.
Combining SomaLogic&#8217;s proteomics technology with Illumina&#8217;s NGS ecosystem,&nbsp;DRAGEN software, and Illumina Connected Multiomics will accelerate the technology development roadmap for proteomics and reduce the time and cost of proteomic research.
SomaLogic has approximately 250 employees worldwide.
This transaction brings SomaLogic&#8217;s aptamer-based affinity proteomics platform into Illumina&#8217;s portfolio, enhancing Illumina&#8217;s presence in a high-growth area within the proteomics market.
The kitted NGS-based panels business will add a high-margin consumables revenue stream.
Illumina expects the business to become profitable in 2027 on a non-GAAP operating income basis and for non-GAAP operating margins to be in line with Illumina in 2028.
Illumina expects to close the transaction in the first half of 2026.
Price Action: LAB stock is up 33.8% at $1.41, and ILMN stock is up 0.09% at $90.57 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45471704/icahn-ramps-up-bets-on-genes-and-jets-illumina-stake-jumps-450-jetblue-holding-grow-90" target="_blank" rel="noreferrer noopener">Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%</a></li>
</ul>
Photo via Shutterstock

Health Care

SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push

ILMN stock has given up its prior gain. Standard BioTools shares were trading higher after the company announced a strategic sale of SomaLogic to Illumina.

CORRECTION: Standard BioToles Ticker Is "LAB" Not "ILMN"

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash&nbsp;&nbsp;
Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business &nbsp; Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even &nbsp; Cash &amp; Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) (the "Company" or "Standard BioTools") today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) ("Illumina"), including SomaScan&#xAE; Assay Services, Authorized Sites and KREX&#x2122; for an upfront payment of $350 million in cash at closing and up to $75 million in cash in near-term milestone payments, for aggregate cash consideration of up to $425 million, plus specified sales royalties on SOMAmer-based next-generation sequencing (NGS) library preparation kits (Illumina Protein Prep). Standard BioTools will retain certain Single SOMAmer reagent commercialization rights. The transaction significantly simplifies the operating structure of Standard BioTools and enables the achievement of adjusted EBITDA break-even.
The transaction is expected to close in the first half of 2026, subject to receipt of required regulatory approvals, including receipt of clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and satisfaction of other customary closing conditions. The transaction has been unanimously approved by both the Standard BioTools Board of Directors and a Special Committee of the Standard BioTools Board of Directors.

Standard BioTools Sells SomaLogic To Illumina For Up To $425M, Plus Future Royalties

Illumina shares are trading higher after the company announced it was selected by Incyte and QIAGEN to advance precision diagnostics for CALR-driven myeloproliferative neoplasms.

Press Releases

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

"Mag 7 Undercard Movers: IBO, SNYR, CTOR, PNPN.V, LAB – Breakthroughs in Military Defense, Tech, Medical & Healthcare Fuel Market Buzz"

Management

iRhythm Technologies Announces Board Member Retirements and New Director Appointments

Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year

Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

ABSI

AIFF

ARAI

CTOR

INCY

IRTC

NRXP

PNPNF

PRSO

QGEN

SNYR

TSXV:PNPN

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Illumina

Noticias

Últimas noticias sobre Illumina (NASDAQ:ILMN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL